Armand MEKONTSO DESSAP
Créteil, Val De Marne, 94010, France
NCT Number: NCT06214845
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC), which may evolve to acute chest syndrome (ACS), the most common cause of death among adult patients with SCD. Currently, there is no etiologic treatment to abort ACS. Therefore, management of ACS mostly involve a symptomatic approach including in routine, and as per recommendations, hydration, analgesics, supplemental oxygen, and transfusion.
The polymerisation of sickle haemoglobin (HbS) is one major feature in the pathogenesis of vaso-occlusion. Current guidelines recommend red blood cell exchange transfusion (REX) in patients with severe ACS in order to improve oxygenation and reduce HbS concentration to blunt sickling. REX is often preferred over simple transfusion in this setting because it rapidly reduces HbS without raising final haematocrit. There are currently two methods for REX: manual (with sequential phlebotomies and transfusions) or automated (erythrocytapheresis). The former allows a sober use of red blood cell packs, while the latter achieves haematological targets (HbS and haematocrit) quickly and more consistently, but requires a special equipment and trained staff. As a result of inflammation and intravascular hemolysis, the plasma of patients with ACS may also contain several components that promote vaso-occlusion, lung injury and organ failure, including cytokines (e.g., IL-6), free haemoglobin and free haem. Conversely, it is depleted in haptoglobin and hemopexin, which normally bind to and clear cell-free haemoglobin. The addition of therapeutic plasma exchange to erythrocytapheresis during automated REX may therefore have a dual beneficial effect in patients with overt intravascular hemolysis: i) deplete the inflammatory mediators and products of hemolysis; ii) replete haptoglobin and hemopexin. REX modalities (automated vs manual) have not been tested during ACS.
The hypothesis is that early-goal directed automated REX may accelerate the resolution of severe ACS as compared to manual REX.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Créteil, Val De Marne, 94010, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single automated REX will be performed, as soon as possible after randomization.
Other names: Automated REX
Time frame: 48 hours after randomization
Time to successful weaning from both supplemental oxygen and any respiratory support, defined as SpO2 ≥ 95% without oxygen and any respiratory support (non-invasive or invasive) during 48 hours.
Time frame: Up to 3 months
Time frame: Up to 3 months
Length of hospital stay
Time frame: Up to 3 months
During hospitalisation and within 28 days and 3 months following randomisation
Time frame: Up to 28 days
high flow nasal oxygen, continuous positive airway pressure, or bilevel non-invasive ventilation)
Time frame: Up to 3 months
Time frame: Up to 3 days
Time frame: 3 and 6 days after randomization
routine laboratory tests including: complete blood count, arterial blood gas, serum creatinine, aspartate and alanine aminotransferase (AST/ALT), total and direct bilirubin, lactate dehydrogenase (LDH), CRP; blood electrolyte panel
Time frame: 3 and 6 days after randomisation
Contact information is provided by the study sponsor or research team.
Assistance Publique - Hôpitaux de Paris
Other
Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease: a Multicentre, Randomised, Clinical Trial
Acronym: ARCAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06698120
Acute Chest Syndrome, Anemia
Paris, France
View Trial DetailsNCT05640271
Acute Chest Syndrome, Anemia
Chicago, Illinois, United States
View Trial DetailsNCT06818266
Acute Chest Syndrome, Anemia
Paris, France
View Trial DetailsNCT06880679
Acute Chest Syndrome, Anemia
Indianapolis, Indiana, United States
View Trial Details